Saturday, July 11, 2026

pharma · Multiple System Atrophy · Asthma

Second Affiliated Hospital

Second Affiliated Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Multiple System Atrophy, Asthma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 paten

Hangzhou, CN HQ
1869 Founded
16 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Hangzhou, CN
Founded
1869
Employees
16
Programs
2
Drugs
4
Patents
0

Quick answer

Second Affiliated Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Multiple System Atrophy, Asthma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1).

Company snapshot

Originally known as Hangzhou Guangji Hospital (meaning “spreading benevolence around the world” or “universal benevolence”), the Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU) was founded in 1869, and was considered the best hospital in the Far East then. As the cradle of western medicine in Zhejiang, SAHZU educated a large number of medical talents, and several health c

  • 2 active pipeline program(s) linked via ClinicalTrials.gov.
  • 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Second Affiliated Hospital. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum signals

Momentum

Proprietary activity score for Second Affiliated Hospital.

1 active signal

13 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 2 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d
Competitive landscape
Recent activity

Recent activity

Latest pipeline, patent, and corporate events for Second Affiliated Hospital.

  1. Clinical update

    Inhaled corticosteriod/long-acting beta-agonist plus Montelukast — Unknown

  2. Clinical update

    3-N-butylphthalide — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Second Affiliated Hospital?

    Second Affiliated Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Multiple System Atrophy, Asthma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTri

  • Is Second Affiliated Hospital publicly traded?

    Second Affiliated Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Second Affiliated Hospital develop or market?

    We link 4 drug profile(s) where Second Affiliated Hospital is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/second-affiliated-hospital-school-of-medicine-zhejiang-university#company-drugs.

  • What are the latest developments for Second Affiliated Hospital?

    In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Second Affiliated Hospital focus on?

    Second Affiliated Hospital focuses on Multiple System Atrophy, Asthma based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
4